Dr. Malek is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Roswell Park Comprehensive Cancer Center
Buffalo, NY 14203
Summary
- Dr. Ehsan Malek is an expert in Multiple Myeloma and Cellular Therapy in Buffalo, NY, and is affiliated with Roswell Park Comprehensive Cancer Center. Has been in practice 13 years. . He has more than 60 publications and over 500 citings.
Education & Training
University of Cincinnati Medical Center/College of MedicineFellowship, Hematology and Medical Oncology, 2011 - 2014
University of Utah HealthResidency, Internal Medicine, 2009 - 2011
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalInternship, Internal Medicine, 2008 - 2009
Shahid Beheshti University of Medical SciencesClass of 2004
Certifications & Licensure
OH State Medical License 2012 - 2026
NY State Medical License 2023 - 2025
UT State Medical License 2010 - 2014
Clinical Trials
- Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma Start of enrollment: 2017 Jul 21
- Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma Start of enrollment: 2023 Dec 01
Publications & Presentations
PubMed
- 85 citationsPharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomibSajjeev Jagannathan, Mohamed A. Y. Abdel-Malek, Ehsan Malek, Nikhil Vad, Tahir Latif
Leukemia. 2015-06-25 - 404 citationsOutcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.Ujjawal H. Gandhi, Robert F. Cornell, Arjun Lakshman, Zhubin Gahvari, Elizabeth McGehee
Leukemia. 2019-09-01 - 34 citationsComparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma.Luciano J. Costa, Yi Lin, R. Frank Cornell, Thomas Martin, Saurabh Chhabra
Clinical Lymphoma, Myeloma & Leukemia. 2021-10-30
Journal Articles
- Influence of Gut Microbiome on Multiple Myeloma: Friend or Foe?Ehsan Malek, MD, Journal For Immunotherapy of Cancer
Abstracts/Posters
- Inotuzumab Ozogamicin Post-Transplant for Acute Lymphocytic LeukemiaEhsan Malek, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Phase 1 Study of on Site Manufactured Anti-CD19 CAR-T Cells: Responses in Subjects with Rapidly Progressive Refractory LymphomasEhsan Malek, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Impact of Previous Cancer Therapy on Outcome of Patients with Multiple Myeloma or Smoldering DiseaseEhsan Malek, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Press Mentions
Wearable Digital Thermometer Detects Fever Quicker Than Current SOC MethodMay 29th, 2018
TempTraq® Detects Fevers Quicker Than the Current Standard-of-Care MethodMay 24th, 2018
Agent Can Decrease GI Toxicity in MM PatientsFebruary 13th, 2018- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
